The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 02, 2024

Filed:

Dec. 04, 2018
Applicants:

The Medical Research Infrastructure and Health Services Fund of the Tel Aviv Medical Center, Tel Aviv, IL;

Yeda Research and Development Co. Ltd., Rehovot, IL;

Inventors:

Zelig Eshhar, Tel Yitzhak, IL;

Tova Waks, Petach Tikva, IL;

Anat Globerson Levin, Tel Aviv, IL;

Moran Rawet Slobodkin, Tel Aviv, IL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 35/17 (2015.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01); C12N 15/63 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 39/001126 (2018.08); A61K 39/001129 (2018.08); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 39/4631 (2023.05); A61P 35/00 (2018.01); C07K 16/28 (2013.01); C07K 16/2896 (2013.01); C07K 16/3061 (2013.01); C12N 5/0636 (2013.01); C12N 5/10 (2013.01); C12N 15/63 (2013.01); A61K 2039/505 (2013.01); C07K 16/30 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/56 (2013.01); C07K 2317/569 (2013.01); C07K 2317/76 (2013.01); C07K 2319/03 (2013.01);
Abstract

The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.


Find Patent Forward Citations

Loading…